CL2022002579A1 - [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2 - Google Patents

[1,3]diazino[5,4-d]pirimidinas como inhibidores de her2

Info

Publication number
CL2022002579A1
CL2022002579A1 CL2022002579A CL2022002579A CL2022002579A1 CL 2022002579 A1 CL2022002579 A1 CL 2022002579A1 CL 2022002579 A CL2022002579 A CL 2022002579A CL 2022002579 A CL2022002579 A CL 2022002579A CL 2022002579 A1 CL2022002579 A1 CL 2022002579A1
Authority
CL
Chile
Prior art keywords
diazino
pyrimidines
her2 inhibitors
her2
inhibitors
Prior art date
Application number
CL2022002579A
Other languages
English (en)
Inventor
Wilding Birgit
Boese Dietrich
Engelhardt Harald
Fuchs Julian
Neumueller Ralph
Petronczki Mark
Scharn Dirk
Treu Matthias
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2022002579A1 publication Critical patent/CL2022002579A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a 1,3diazino5,4-dpirimidinas novedosas y derivados de la Fórmula (I), en donde los grupos R1, R2, R3 y R4 tienen los significados que se proporcionan en las reivindicaciones y la memoria descriptiva, su uso como inhibidores de HER2 y sus mutantes, composiciones farmacéuticas que contienen tales compuestos y su uso como medicamentos, especialmente como agentes para el tratamiento y/o la prevención de enfermedades oncológicas.
CL2022002579A 2020-04-24 2022-09-23 [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2 CL2022002579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20171221 2020-04-24

Publications (1)

Publication Number Publication Date
CL2022002579A1 true CL2022002579A1 (es) 2023-05-19

Family

ID=70470818

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002579A CL2022002579A1 (es) 2020-04-24 2022-09-23 [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2

Country Status (19)

Country Link
US (2) US11608343B2 (es)
EP (1) EP4139309A1 (es)
JP (2) JP7260723B2 (es)
KR (1) KR20230005263A (es)
CN (13) CN118307544A (es)
AR (1) AR121779A1 (es)
AU (1) AU2021260721A1 (es)
BR (1) BR112022021514A2 (es)
CA (1) CA3173602A1 (es)
CL (1) CL2022002579A1 (es)
CO (1) CO2022015054A2 (es)
CR (1) CR20220537A (es)
DO (1) DOP2022000189A (es)
EC (1) ECSP22072777A (es)
IL (1) IL297490A (es)
MX (1) MX2022013223A (es)
PE (1) PE20230827A1 (es)
TW (1) TW202206432A (es)
WO (1) WO2021213800A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
PE20240327A1 (es) 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
WO2022266458A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 6-heterocycloalkyl-quinazoline derivatives and uses thereof
WO2023154124A1 (en) * 2022-02-09 2023-08-17 Enliven Therapeutics, Inc. Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2
KR20230143959A (ko) * 2022-04-05 2023-10-13 보로노이 주식회사 헤테로아릴 유도체 및 이의 용도
CN117384162A (zh) * 2022-05-17 2024-01-12 浙江文达医药科技有限公司 选择性her2抑制剂
WO2024027695A1 (zh) * 2022-08-04 2024-02-08 微境生物医药科技(上海)有限公司 作为her2抑制剂的化合物
US20240226103A1 (en) 2022-12-22 2024-07-11 Boehringer Ingelheim International Gmbh Solid dispersion of a her2 inhibitor
US20240279230A1 (en) 2022-12-22 2024-08-22 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor
WO2024133325A1 (en) 2022-12-22 2024-06-27 Boehringer Ingelheim International Gmbh Dosing schedule of a solid dispersion of a her2 inhibitor
WO2024200637A2 (en) 2023-03-29 2024-10-03 Boehringer Ingelheim International Gmbh Dosing schedule of a her2 inhibitor
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW414798B (en) * 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HUP0501069A2 (en) 2001-12-12 2006-06-28 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
MXPA06005024A (es) 2003-11-06 2006-07-06 Pfizer Prod Inc Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer.
ZA200804498B (en) 2005-11-15 2009-07-29 Array Biopharma Inc N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ERBB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
JP6468611B2 (ja) 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
MA40240B1 (fr) 2014-06-19 2019-03-29 Ariad Pharma Inc Composés hétéroaryle d'inhibition de la kinase
EP3294712A4 (en) 2015-05-13 2018-11-07 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN115322193A (zh) 2017-08-31 2022-11-11 达纳-法伯癌症研究所股份有限公司 Egfr和/或her2抑制剂和使用方法
EP3677583A4 (en) 2017-09-01 2021-07-21 Shanghai Pharmaceuticals Holding Co., Ltd. NITROGEN HETEROCYCLIC COMPOUND, MANUFACTURING PROCESS, INTERMEDIATE, COMPOSITION AND USE
JP2023512175A (ja) 2020-02-03 2023-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
JP2023512174A (ja) 2020-02-03 2023-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
WO2021231400A1 (en) 2020-05-12 2021-11-18 Accutar Biotechnology, Inc. Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors

Also Published As

Publication number Publication date
WO2021213800A1 (en) 2021-10-28
CN115485277B (zh) 2024-05-14
EP4139309A1 (en) 2023-03-01
PE20230827A1 (es) 2023-05-19
CO2022015054A2 (es) 2023-02-16
IL297490A (en) 2022-12-01
CN118619956A (zh) 2024-09-10
US11608343B2 (en) 2023-03-21
CA3173602A1 (en) 2021-10-28
TW202206432A (zh) 2022-02-16
DOP2022000189A (es) 2022-09-30
CN115485277A (zh) 2022-12-16
CN118388493A (zh) 2024-07-26
JP2023085489A (ja) 2023-06-20
CR20220537A (es) 2022-12-06
US20230374021A1 (en) 2023-11-23
CN118388487A (zh) 2024-07-26
ECSP22072777A (es) 2022-10-31
AR121779A1 (es) 2022-07-06
CN118388490A (zh) 2024-07-26
CN118388492A (zh) 2024-07-26
CN118388491A (zh) 2024-07-26
US20210332054A1 (en) 2021-10-28
JP2023512343A (ja) 2023-03-24
CN118388489A (zh) 2024-07-26
CN118388495A (zh) 2024-07-26
CN118388494A (zh) 2024-07-26
CN118307543A (zh) 2024-07-09
AU2021260721A1 (en) 2022-09-15
CN118388488A (zh) 2024-07-26
CN118307544A (zh) 2024-07-09
KR20230005263A (ko) 2023-01-09
MX2022013223A (es) 2022-11-14
JP7260723B2 (ja) 2023-04-18
BR112022021514A2 (pt) 2023-01-24

Similar Documents

Publication Publication Date Title
CO2022015054A2 (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2
CL2021000907A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020)
UY39296A (es) Azaquinolonas sustituidas inhibidoras de parp y composiciones farmacéuticas que las contienen
DOP2022000266A (es) 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer
ECSP21080740A (es) Inhibidores del inflamasoma nlrp3
CL2021000191A1 (es) Inhibidores de inflamasoma nlrp3
BR112018007155A2 (pt) novos compostos de espiro[3h-indol-3,2?-pirrolidin]-2(1h)-ona e derivados como inibidores de mdm2-p53
UY30681A1 (es) Compuestos de piridinamida que contienen carboxi, sales farmacéuticamente aceptables, procedimientos para la preparacion de los mismos, composiciones que los contienen y sus usos.
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
CL2012000059A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidina; proceso de preparacion; composicion farmaceutica que los comprende; y su uso como inhbidores de trk-quinasa para el tratamiento de enfermedades o trastornos tales como dolor, cancer, inflamacion; entre otras.
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
UY31063A1 (es) Derivados de n-[6-amino-5-aril-piridin -2-il]-carboxamida, composiciones conteniéndolos, procedimientos de preparación, itermedios utilizados en la preparación y aplicaciones.
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
UY28695A1 (es) Derivados de difenilazetidona
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2022003646A1 (es) Derivados de amidopirimidona
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
UY29394A1 (es) Derivados sustituidos de n-(5-(2-propilamino.1.hidroxietil)-2-hdroxifenil) metano sulfonamida, composiciones farmacéuticas que lo contienen y aplicaciónes.
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
CL2021000282A1 (es) Inhibidores de ckd8/19
UY31805A (es) Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor
GT200500214A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon